David Bearss

Company: Halia Therapeutics

Job title: President & Chief Executive Officer ,Co-Founder

Bio:

Dr. David Bearss is an accomplished cancer biologist, drug developer, and biotech entrepreneur with over two decades of experience translating groundbreaking science into clinical innovation. Dr. Bearss has discovered 18 drugs that have entered clinical trials and has started eight biotechnology companies. He currently serves as Chief Executive Officer of Halia Therapeutics, where he leads the development of first-in-class therapies, modulating the immune system role in chronic inflammation, including Ofirnoflast (HT-6184), a selective allosteric inhibitor of the NEK7-NLRP3 inflammasome interaction.

Seminars:

Reprogramming Immunometabolism: Ofirnoflast & GLP-1 Synergy in the Next Generation of Obesity Therapies 3:10 pm

A Dual-Targeted Strategy: Combining the metabolic effects of GLP-1 receptor agonists with Ofirnoflast’s direct inhibition of the NEK7-NLRP3 inflammasome tackles both appetite regulation and the chronic inflammation that underlies obesity and insulin resistance Enhanced Weight Loss and Glycemic Control: Preclinical studies demonstrate true synergy between Ofirnoflast and semaglutide, yielding superior reductions in weight, inflammatory markers,…Read more

day: Day One